Ultragenyx Pharmaceutical Inc. RARE
17.16 USD +0.53 (+3.19%)
At closeNov 4, 2026, 5:03 PM EST
17.16 0.00 0.00%
After hours · Nov 4, 5:03 PM ET
16.23 Day range 17.67
12.88 52-week range 36.54
- YTD
- -25.39%
- 1 year
- -47.13%
News
benzinga.com Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $34 Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $39 to $34.
benzinga.com TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $19 TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $18 to $19.
benzinga.com Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22 Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $20 to $22.- benzinga.com Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17 Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $19 to $17.
seekingalpha.com Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains…- benzinga.com Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $22 Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $25 to $22.
benzinga.com Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs Ultragenyx cuts 20% of staff and trims pipeline programs after missing Q3 targets, aiming for 2027 profitability through new commercial launches.
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
seekingalpha.com Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis -…
marketbeat.com What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and…
zacks.com Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.
zacks.com Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
benzinga.com Ultragenyx Pharmaceutical Q3 2026 Earnings Call Transcript Ultragenyx Pharmaceutical (NASDAQ:RARE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Ultragenyx Pharmaceutical Announces UX701 AAV9 Gene Therapy To Treat Wilson Disease Failed To Meet Criteria, Being Terminated Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today…
benzinga.com Ultragenyx Pharmaceutical Eliminating ~20% Employees Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…- benzinga.com Ultragenyx Pharmaceutical Affirms FY2026 Sales Guidance of $730.000M-$760.000M vs $762.256M Est Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2026 sales outlook from $730.000 million-$760.000 million to $730.000 million-$760.000 million vs $762.256 million estimate.
- benzinga.com Ultragenyx Pharmaceutical Q3 EPS $(1.16) Misses $(1.12) Estimate, Sales $173.000M Miss $183.118M Estimate Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(1.12) by 3.57 percent. This is a 35.91 percent increase over…
globenewswire.com Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review…
globenewswire.com Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for…
prnewswire.com AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New…
zacks.com Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report) CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an…
benzinga.com Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending On October 19, 2026, Ultragenyx Pharmaceutical Inc. (the "Company") and Baylor Research Institute ("BRI") entered into a settlement agreement with Navinta LLC ("Navinta") resolving patent- benzinga.com UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16 UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.
zacks.com RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
zacks.com Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
globenewswire.com Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following…
defenseworld.net Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM) Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE: TSM). In a filing disclosed on October 12th, the…
defenseworld.net Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE) Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
zacks.com Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
proactiveinvestors.com Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210…- benzinga.com Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review Voucher Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.…
globenewswire.com Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such…
zacks.com Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
globenewswire.com Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its…
benzinga.com Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18 Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.- benzinga.com Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $35 Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $32 to $35.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $20 Morgan Stanley analyst Maxwell Skor maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Equal-Weight and raises the price target from $18 to $20.
benzinga.com Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.- benzinga.com Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $39 Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $37 to $39.
- benzinga.com Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $39 Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $33 to $39.
- benzinga.com Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.
benzinga.com Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo…- benzinga.com Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19 Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.
benzinga.com This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday Analysts downgraded UiPath, Cal-Maine with several price-target cuts.- benzinga.com Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32 Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $43 to $32.
- benzinga.com JP Morgan Downgrades Ultragenyx Pharmaceutical to Neutral, Lowers Price Target to $36 JP Morgan analyst Anupam Rama downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) from Overweight to Neutral and lowers the price target from $80 to $36.
- benzinga.com Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $28 Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $77 to $28.